Glenmark receives final ANDA approval for Omeprazole DR capsules

It is a generic version of Prilosec by AstraZeneca

Glenmark Generics has been granted final approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration (US FDA) for omeprazole delayed release capsules, their generic version of Prilosec by AstraZeneca.

Omeprazole DR capsules are indicated for the short-term treatment of active duodenal ulcer in adults. The approval is for the 10, 20, and 40mg strengths of Omeprazole. According to IMS Health sales data for the 12 month period ending September 2014, Omeprazole garnered annual sales of approximately US $520 million.

Glenmark’s current portfolio consists of 94 products authorised for distribution in the US marketplace and 72 ANDA’s pending approval with the US FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

EP News BureauMumbai